Amantadine Therapy for Fatigue in Multiple Sclerosis

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

Volumn 12, Issue 3, 1985, Pages 251-254

  Murray, T J ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BACLOFEN; METHYLPHENIDATE; PLACEBO; PYRIDOSTIGMINE;

ADVERSE DRUG REACTION; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG THERAPY; FATIGUE; GASTRITIS; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; HYPERACTIVITY; INFLUENZA; INTOXICATION; MULTIPLE SCLEROSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SKIN TOXICITY; SLEEP DISORDER; STOMACH; THERAPY;

AMANTADINE; CLINICAL TRIALS; FATIGUE; HUMAN; MULTIPLE SCLEROSIS;

EID: 0022257683     PISSN: 03171671     EISSN: 20570155     Source Type: Journal    
DOI: 10.1017/S0317167100047107     Document Type: Article

References (16)

1. MacAlpine D, Lumsden CE, Acheson E.D. Multiple Sclerosis: A reappraisal. Edinburgh: Churchill Livingston 1972; 115–116.
2. Herndon RM, Rudick R. Fatigue in M.S. M.S. Quarterly. Summer 1981; 4–14.
3. Sandy KR. Anergia and depression as early features of Multiple Sclerosis. S Afr Med J 1983; 732.
4. Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's Disease. JAMA 1969; 208: 1168.
5. Gray MW, Herzberg L, Lenman JAR, et al. Anantadine in chorea. Lancet 1975; 2: 132–133.
6. Schunk W. Manganese poisoning. Dsch Gesundh Wes 1976; 31: 1847.
7. Haslam RHA, McQuillen MP, Clark DB. Amantadine Therapy in subacute sclerosing panencephalitis. Neurology 1969; 19: 1080.
8. Pacifici GM, Nardini M, Ferrari P, et al. Effect of Amantadine on drug-induced Parkinsonism: relationship between plasma levels and effect. Br J Clin Pharmac 1976: 3: 883.
9. Rizzo M, Biandrate P, Tognoni G, et al. Amantadine in depression: relationship between behavioral effects and plasma levels. Europ J Clin Pharmacol 1973; 5: 226–228.
10. Chierichetti SM, Ferrari P, Sala P, et al. Effects of Amantadine on mental status of elderly patients. Curr Ther Rs 1977; 22: 158–165.
11. White G. Improving babies with down's syndrome. Med J Australia 1974; 2: 184.
12. Critchley E. Clinical Manifestations of Essential Tremor. J Neuro Neurosurg Psychiat 1972; 35: 365–372.
13. MacDonald JR. Empirical use of amantadine in Multiple Sclerosis. Wink CAS (ed) Symmetrel in Virology. Geigy Pharm Macdesfield p 48–50.
14. Schapira M. Amantadine in the treatment of Multiple Sclerosis. J Roy Coll Gen Prac 1974; 2: 411–413.
15. Ellison GW, Mickey MR, Myers LW, et al. A Pilot study of Amantadine treatment of Multiple Sclerosis. In: Progress in Multiple Sclerosis Research. Bauer HF, Doser S, Ritter G, (eds) Berlin: Springer Verlag 1980; 407.
16. Freal JE, Kraft GH, Coryell JK. Symptomatic Fatigue in Multiple Sclerosis. Arch Phys Med Rehabil 1984; 65: 135–138.